Weekly Endocrinology Research Analysis
This week’s endocrinology research was dominated by precision approaches to diabetes, obesity, and endocrine-related complications. The strongest translational findings included direct intrarenal evidence that SGLT2 inhibition remodels metabolic, vascular, and inflammatory pathways in youth with type 1 diabetes, a large nationwide study showing that severity and rapid worsening of new-onset diabetes stratify pancreatic cancer risk, and a mechanistic study identifying palmitic acid–CREBZF disrupt
Summary
This week’s endocrinology research was dominated by precision approaches to diabetes, obesity, and endocrine-related complications. The strongest translational findings included direct intrarenal evidence that SGLT2 inhibition remodels metabolic, vascular, and inflammatory pathways in youth with type 1 diabetes, a large nationwide study showing that severity and rapid worsening of new-onset diabetes stratify pancreatic cancer risk, and a mechanistic study identifying palmitic acid–CREBZF disruption of visceral adipose Tregs as a driver of metabolic inflammation. Additional clinically relevant advances included automated MRI assessment of thyroid-associated ophthalmopathy, lipid-guided menopausal hormone therapy selection, and microbiota-derived IAA therapy concepts for PCOS.
Selected Articles
1. SGLT2 inhibition modulates metabolic, vascular, and inflammatory molecular markers in the kidney in youth with type 1 diabetes.
In the placebo-controlled ATTEMPT trial, 98 youth with type 1 diabetes and hyperfiltration received dapagliflozin or placebo for 16 weeks. Sequential human kidney biopsies in adults, MRI, and proteomics showed that SGLT2 inhibition reshaped intrarenal metabolic, vascular, and inflammatory pathways, providing direct mechanistic evidence for potential renoprotection in type 1 diabetes.
Impact: This is an unusually rigorous human mechanistic study combining randomization, sequential kidney biopsies, MRI, and multi-omics in type 1 diabetes. It directly maps drug effects within the kidney rather than inferring them only from circulating biomarkers or clinical outcomes.
Clinical Implications: The findings support further trials of kidney-protective SGLT2 strategies in carefully selected patients with type 1 diabetes and may enable development of intrarenal biomarkers and surrogate endpoints. They do not yet establish long-term clinical benefit or resolve safety considerations such as ketoacidosis risk.
Key Findings
- Ninety-eight youth with type 1 diabetes and hyperfiltration were randomized to dapagliflozin 5 mg or placebo for 16 weeks.
- Sequential kidney biopsies, MRI, and proteomics demonstrated modulation of intrarenal metabolic, vascular, and inflammatory pathways.
2. Impact of initial severity and progression pattern of new-onset diabetes on pancreatic cancer risk: a 15-year longitudinal nationwide cohort study.
In a 402,663-person Korean nationwide cohort, pancreatic cancer risk increased stepwise with the initial treatment intensity of new-onset diabetes. Rapid escalation of diabetes therapy within six months identified an even higher-risk subgroup, particularly for pancreatic cancer diagnosed within three years of diabetes onset.
Impact: The study advances risk assessment beyond the simple presence or absence of diabetes by using clinically accessible measures of initial severity and early progression. Its very large population and 15-year longitudinal design provide a strong foundation for risk-stratified evaluation of secondary diabetes and pancreatic disease.
Clinical Implications: Rapidly worsening glycemia or early treatment intensification should prompt consideration of secondary diabetes and pancreatic symptoms, including weight loss, while avoiding indiscriminate imaging. The findings support targeted surveillance research but do not yet establish a universal pancreatic imaging strategy.
Key Findings
- Compared with individuals without diabetes, pancreatic cancer hazard ratios were 3.01, 4.32, and 5.60 for new-onset diabetes requiring no medication, oral medication, and insulin, respectively.
- Treatment escalation within six months further increased pancreatic cancer risk within the same baseline treatment category.
3. Palmitic acid coordinates impaired visceral adipose ICOShi Treg-mediated immunosuppression and systemic metabolic disturbance during obesity.
This mechanistic study identified a palmitic acid–CREBZF–c-JUN pathway that suppresses FOXP3 activity and destabilizes ICOShi regulatory T cells in visceral adipose tissue. CREBZF deficiency or transfer of CREBZF-deficient Tregs reduced diet-induced obesity, inflammation, and metabolic dysfunction, while human adipose Tregs showed elevated CREBZF and reduced FOXP3 activity.
Impact: The study provides a detailed molecular bridge between saturated-fat exposure, adipose immune dysfunction, and systemic metabolic disease. Its validation across diet-induced and genetic obesity models, adoptive transfer experiments, and human tissue analyses makes CREBZF a credible target for future immunometabolic therapies.
Clinical Implications: The findings support development of therapies that restore adipose Treg function and reinforce dietary strategies that reduce excessive saturated-fat exposure. However, CREBZF-targeted treatment remains preclinical, and human dose-response, safety, and causal intervention studies are required.
Key Findings
- Palmitic acid, but not oleic acid, induced Crebzf in visceral adipose Tregs and impaired their immunosuppressive function.
- CREBZF interacted with c-JUN to inhibit FOXP3, while Crebzf deficiency improved obesity-associated inflammation and metabolic dysfunction.